• Citer

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

par Loibl, Sibylle;Loirat, Delphine;Tolaney, Sara S.M.;Punie, Kevin;Oliveira, Mafalda;Rugo, Hope H.S.;Bardia, Aditya;Hurvitz, Sara;Brufsky, Adam;Kalinsky, Kevin;Cortes, Javier;O'Shaughnessy, Joyce;Diéras, Veronique;Carey, Lisa L.A.;Gianni, Luca;Gharaibeh, Mahdi;Preger, Luciana;Phan, See;Chang, Lawrence;Shi, Ling;Piccart-Gebhart, Martine
Référence European journal of cancer, 178, page (23-33)
Publication Publié, 2023-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Auteur:	Loibl, Sibylle; Loirat, Delphine; Tolaney, Sara S.M.; Punie, Kevin; Oliveira, Mafalda; Rugo, Hope H.S.; Bardia, Aditya; Hurvitz, Sara; Brufsky, Adam; Kalinsky, Kevin; Cortes, Javier; O'Shaughnessy, Joyce; Diéras, Veronique; Carey, Lisa L.A.; Gianni, Luca; Gharaibeh, Mahdi; Preger, Luciana; Phan, See; Chang, Lawrence; Shi, Ling; Piccart-Gebhart, Martine
Informations sur la publication:	European journal of cancer, 178, page (23-33)
Statut de publication:	Publié, 2023-01
Sujet CREF:	Cancérologie
Mots-clés:	Antibody–drug conjugate
	Clinical trial
	EORTC QLQ-C30
	Phase III
	Quality of life
	Sacituzumab govitecan
	Triple-negative breast neoplasms
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2022.10.003
	info:pii/S0959804922007997
	info:scp/85141747362
	info:pmid/36379186